ARTIVION INC (AORT) Stock Fundamental Analysis
NYSE:AORT - US2289031005 - Common Stock
43.81 USD
+0.07 (+0.16%)
43.81 USD
0 (0%)
AORT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of AORT get a neutral evaluation. Nothing too spectacular is happening here. AORT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
AORT had negative earnings in the past year.
AORT had a positive operating cash flow in the past year.
AORT had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: AORT reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of AORT (-2.13%) is better than 67.03% of its industry peers.
With a decent Return On Equity value of -4.26%, AORT is doing good in the industry, outperforming 67.57% of the companies in the same industry.
AORT has a better Return On Invested Capital (2.15%) than 69.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.13% | ||
| ROE | -4.26% | ||
| ROIC | 2.15% |
ROA(3y)-2.68%
ROA(5y)-2.4%
ROE(3y)-7.46%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AORT's Operating Margin of 5.18% is fine compared to the rest of the industry. AORT outperforms 69.19% of its industry peers.
AORT's Operating Margin has improved in the last couple of years.
AORT has a better Gross Margin (63.99%) than 66.49% of its industry peers.
AORT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.18% | ||
| PM (TTM) | N/A | ||
| GM | 63.99% |
OM growth 3Y31.35%
OM growth 5Y5.5%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AORT is destroying value.
Compared to 1 year ago, AORT has more shares outstanding
Compared to 5 years ago, AORT has more shares outstanding
The debt/assets ratio for AORT is higher compared to a year ago.
2.2 Solvency
AORT has an Altman-Z score of 3.78. This indicates that AORT is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.78, AORT is in the better half of the industry, outperforming 73.51% of the companies in the same industry.
AORT has a debt to FCF ratio of 28.63. This is a negative value and a sign of low solvency as AORT would need 28.63 years to pay back of all of its debts.
AORT has a Debt to FCF ratio of 28.63. This is in the better half of the industry: AORT outperforms 67.57% of its industry peers.
AORT has a Debt/Equity ratio of 0.52. This is a neutral value indicating AORT is somewhat dependend on debt financing.
The Debt to Equity ratio of AORT (0.52) is worse than 62.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 28.63 | ||
| Altman-Z | 3.78 |
ROIC/WACC0.25
WACC8.52%
2.3 Liquidity
A Current Ratio of 4.78 indicates that AORT has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.78, AORT is doing good in the industry, outperforming 75.14% of the companies in the same industry.
A Quick Ratio of 3.48 indicates that AORT has no problem at all paying its short term obligations.
AORT's Quick ratio of 3.48 is fine compared to the rest of the industry. AORT outperforms 70.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.78 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
The earnings per share for AORT have decreased strongly by -12.12% in the last year.
The Revenue has been growing slightly by 7.44% in the past year.
AORT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.06% yearly.
EPS 1Y (TTM)-12.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%260%
Revenue 1Y (TTM)7.44%
Revenue growth 3Y9.14%
Revenue growth 5Y7.06%
Sales Q2Q%15.26%
3.2 Future
Based on estimates for the next years, AORT will show a very strong growth in Earnings Per Share. The EPS will grow by 46.79% on average per year.
The Revenue is expected to grow by 11.89% on average over the next years. This is quite good.
EPS Next Y126.84%
EPS Next 2Y75.59%
EPS Next 3Y50.72%
EPS Next 5Y46.79%
Revenue Next Year11.74%
Revenue Next 2Y11.27%
Revenue Next 3Y11.48%
Revenue Next 5Y11.89%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AORT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 94.07, which means the current valuation is very expensive for AORT.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AORT indicates a somewhat cheap valuation: AORT is cheaper than 65.95% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.78. AORT is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 94.07 |
4.2 Price Multiples
64.86% of the companies in the same industry are more expensive than AORT, based on the Enterprise Value to EBITDA ratio.
AORT's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. AORT is cheaper than 65.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 269.73 | ||
| EV/EBITDA | 50.24 |
4.3 Compensation for Growth
AORT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AORT's earnings are expected to grow with 50.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y75.59%
EPS Next 3Y50.72%
5. Dividend
5.1 Amount
AORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
43.81
+0.07 (+0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners91.56%
Inst Owner ChangeN/A
Ins Owners4.91%
Ins Owner Change13.57%
Market Cap2.07B
Analysts86.15
Price Target42.52 (-2.94%)
Short Float %3.21%
Short Ratio2.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1009.98%
Min EPS beat(2)91.71%
Max EPS beat(2)1928.24%
EPS beat(4)3
Avg EPS beat(4)376.32%
Min EPS beat(4)-537.25%
Max EPS beat(4)1928.24%
EPS beat(8)5
Avg EPS beat(8)158.13%
EPS beat(12)8
Avg EPS beat(12)112.3%
EPS beat(16)10
Avg EPS beat(16)39.11%
Revenue beat(2)2
Avg Revenue beat(2)2.37%
Min Revenue beat(2)2.16%
Max Revenue beat(2)2.59%
Revenue beat(4)2
Avg Revenue beat(4)-0.38%
Min Revenue beat(4)-5.37%
Max Revenue beat(4)2.59%
Revenue beat(8)5
Avg Revenue beat(8)0.72%
Revenue beat(12)7
Avg Revenue beat(12)0.63%
Revenue beat(16)10
Avg Revenue beat(16)0.53%
PT rev (1m)27.42%
PT rev (3m)28.93%
EPS NQ rev (1m)-73.69%
EPS NQ rev (3m)-87.25%
EPS NY rev (1m)2.85%
EPS NY rev (3m)17.04%
Revenue NQ rev (1m)2.38%
Revenue NQ rev (3m)1.83%
Revenue NY rev (1m)2.48%
Revenue NY rev (3m)2.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 94.07 | ||
| P/S | 5.1 | ||
| P/FCF | 269.73 | ||
| P/OCF | 105.18 | ||
| P/B | 4.92 | ||
| P/tB | 269.84 | ||
| EV/EBITDA | 50.24 |
EPS(TTM)-0.37
EYN/A
EPS(NY)0.47
Fwd EY1.06%
FCF(TTM)0.16
FCFY0.37%
OCF(TTM)0.42
OCFY0.95%
SpS8.58
BVpS8.9
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.13% | ||
| ROE | -4.26% | ||
| ROCE | 2.72% | ||
| ROIC | 2.15% | ||
| ROICexc | 2.31% | ||
| ROICexgc | 5.42% | ||
| OM | 5.18% | ||
| PM (TTM) | N/A | ||
| GM | 63.99% | ||
| FCFM | 1.89% |
ROA(3y)-2.68%
ROA(5y)-2.4%
ROE(3y)-7.46%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y37.89%
ROICexcg growth 5Y4.3%
ROICexc growth 3Y45.07%
ROICexc growth 5Y7.68%
OM growth 3Y31.35%
OM growth 5Y5.5%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-0.68%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 28.63 | ||
| Debt/EBITDA | 4.93 | ||
| Cap/Depr | 51.26% | ||
| Cap/Sales | 2.96% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 44.29% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.78 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 3.78 |
F-Score4
WACC8.52%
ROIC/WACC0.25
Cap/Depr(3y)42.06%
Cap/Depr(5y)43.23%
Cap/Sales(3y)2.8%
Cap/Sales(5y)3.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%260%
EPS Next Y126.84%
EPS Next 2Y75.59%
EPS Next 3Y50.72%
EPS Next 5Y46.79%
Revenue 1Y (TTM)7.44%
Revenue growth 3Y9.14%
Revenue growth 5Y7.06%
Sales Q2Q%15.26%
Revenue Next Year11.74%
Revenue Next 2Y11.27%
Revenue Next 3Y11.48%
Revenue Next 5Y11.89%
EBIT growth 1Y-22.98%
EBIT growth 3Y43.36%
EBIT growth 5Y12.95%
EBIT Next Year108.87%
EBIT Next 3Y43.35%
EBIT Next 5Y33.94%
FCF growth 1Y224.1%
FCF growth 3YN/A
FCF growth 5Y7.33%
OCF growth 1Y335.36%
OCF growth 3YN/A
OCF growth 5Y7.04%